α-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: Expression and survival analysis

Konstantin Shilo, Tatiana Dracheva, Haresh Mani, Junya Fukuoka, Isabell A. Sesterhenn, Wei Sing Chu, Joanna H. Shih, Jin Jen, William D. Travis, Teri J. Franks

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Context. - α-Methylacyl CoA racemase (AMACR) is an oxidative enzyme involved in isomeric transformation of fatty acids entering the beta-oxidation pathway. AMACR serves as a useful marker in establishing a diagnosis of prostatic malignancy; however, limited information is available in regard to its presence in pulmonary neoplasms. Objective. - To investigate AMACR expression within a spectrum of lung carcinomas and its correlation with patients' survival. Design. - Four hundred seventy-seven pulmonary carcinomas, including 150 squamous cell carcinomas, 150 adenocarcinomas, 46 typical carcinoids, 31 atypical carcinoids, 28 large cell neuroendocrine carcinomas, and 72 small cell carcinomas, were studied immunohistochemically using tissue microarray-based samples. Results. - Overall, pulmonary tumors were positive for AMACR in a significant percentage (47%) of cases. Among tumor types, 22% of squamous cell carcinoma, 56% of adenocarcinoma, 72% of typical carcinoid, 52% of atypical carcinoid, 70% of large cell neuroendocrine carcinoma, and 51 % of small cell lung carcinoma were positive for AMACR. Furthermore, the Kaplan-Meier analysis revealed that the patients with AMACR-positive small cell carcinoma had better survival (19% vs 5% after 5 years, P = .04) than patients with AMACR-negative tumors. Such survival advantage was seen for patients with stage I-II (P = .01) but not stage IM-IV small cell carcinomas (P = .58). Conclusions. - These results indicate that, similar to prostate cancer, the overexpression of AMACR frequently occurs in pulmonary carcinomas. Additionally, its positive correlation with outcome of stage I-II small cell lung carcinoma warrants further investigation of the AMACR role in the prognosis of this tumor.

Original languageEnglish (US)
Pages (from-to)1555-1560
Number of pages6
JournalArchives of Pathology and Laboratory Medicine
Volume131
Issue number10
StatePublished - Oct 1 2007

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Fingerprint Dive into the research topics of 'α-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: Expression and survival analysis'. Together they form a unique fingerprint.

  • Cite this

    Shilo, K., Dracheva, T., Mani, H., Fukuoka, J., Sesterhenn, I. A., Chu, W. S., Shih, J. H., Jen, J., Travis, W. D., & Franks, T. J. (2007). α-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: Expression and survival analysis. Archives of Pathology and Laboratory Medicine, 131(10), 1555-1560.